Y. Kim and M. W. Brechbiel, An overview of targeted alpha therapy, Tumor Biol, vol.33, p.573, 2012.

K. Yong and M. W. Brechbiel, Towards translation of 212Pb as a clinical therapeutic; getting the lead in!, Dalton Trans, vol.40, p.6068, 2011.

D. R. Corson, K. R. Mackenzie, and E. Segrè, Possible production of radioactive isotopes of element 85, Phys Rev, vol.57, p.1087, 1940.

E. K. Hyde, The present status of elements 85 and 87, J Phys Chem, vol.58, p.21, 1954.

L. Gmelin, K. Berei, and H. K. Kugler, Gmelin Handbook of Inorganic Chemistry: At, Astatine, 1985.

S. Palm, J. L. Humm, and R. Rundqvist, Microdosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusion, Med Phys, vol.31, p.218, 2004.

T. G. Turkington, M. R. Zalutsky, and R. J. Jaszczak, Measuring astatine-211 distributions with SPECT, Phys Med Biol, vol.38, p.1121, 1993.

G. J. Meyer and R. M. Lambrecht, Excitation function for the 209-Bi(7-Li,5n)211-Rn nuclear reaction as a route to the 211-Rn-211-At generator, J Label Compd Radiopharm, vol.28, p.233, 1981.

A. M. Vinodkumar, W. Loveland, and P. H. Sprunger, Fusion of 9 Li with 208 Pb, Phys Rev C, vol.80, p.54609, 2009.

J. Harrison, R. Leggett, and D. Lloyd, Polonium-210 as a poison, J Radiol Prot, vol.27, p.17, 2007.

M. R. Zalutsky and M. Pruszynski, Astatine-211: Production and availability, Current Radiopharm, vol.4, p.177, 2011.

A. Hermanne, F. Tárkányi, and S. Takács, Experimental study of the cross-sections of [alpha]-particle induced reactions on 209 Bi, Appl Radiat Isot, vol.63, p.1, 2005.

S. Lindegren, T. Bä-ck, and H. J. Jensen, Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields, Appl Radiat Isot, vol.55, p.157, 2001.

A. Yordanov, O. Pozzi, and S. Carlin, Wet harvesting of nocarrier-added 211 At from an irradiated 209 Bi target for radiopharmaceutical applications, J Radioanal Nucl Chem, vol.262, p.593, 2005.

C. Alliot, M. Cherel, and J. Barbet, Extraction of astatine-211 in diisopropylether (DIPE), Radiochim Acta, vol.97, p.161, 2009.
URL : https://hal.archives-ouvertes.fr/in2p3-00382729

M. Bourgeois, F. Guerard, and C. Alliot, Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction, J Label Compd Radiopharm, vol.51, p.379, 2008.

M. R. Zalutsky, X. G. Zhao, and K. L. Alston, High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use, J Nucl Med, vol.42, p.1508, 2001.

E. H. Appelman, E. N. Sloth, and M. H. Studier, Observation of astatine compounds by time-of-flight mass spectrometry, Inorg Chem, vol.5, p.766, 1966.

G. L. Johnson, R. F. Leininger, and E. Segrè, Chemical properties of astatine. I, J Chem Phys, vol.17, p.1, 1949.

E. H. Appelman, The oxidation states of astatine in aqueous solution, J Am Chem Soc, vol.83, p.805, 1961.

G. Visser and E. L. Diemer, Inorganic astatine chemistry: Formation of complexes of astatine, Radiochim Acta, vol.33, p.145, 1983.

G. Visser, Inorganic astatine chemistry part II: The chameleon behaviour and electrophilicity of At-species, Radiochim Acta, vol.47, p.97, 1989.

I. Dreyer, R. Dreyer, and V. A. Chalkin, Investigation of the movement of astatine in an electric field, Radiochem Radioanal Lett, vol.35, p.257, 1978.

I. Dreyer, R. Dreyer, and V. A. Chalkin, Cations of astatine in water: illustration and properties, Radiochem Radioanal Lett, vol.36, p.389, 1978.

R. Dreyer, I. Dreyer, and F. Rosch, Studies of polyhalogenide ions of astatine, Radiochem Radioanal Lett, vol.54, p.165, 1982.

T. J. Ruth, D. 'auria, J. M. Dombsky, and M. , The Radiochemistry of Astatine. DOE sponsored Nuclear Science Series monogram

, Available at www .ntis.gov/search/product.aspx?, ABBR = DE88015386 Accessed on, 1988.

M. Pruszy?-ski, A. Bilewicz, and B. W?s, Formation and stability of astatide-mercury complexes, J Radioanal Nucl Chem, vol.268, p.91, 2006.

M. Pruszy?-ski, A. Bilewicz, and M. R. Zalutsky, Preparation of Rh[16aneS4-diol] 211 At and Ir[16aneS4-diol] 211 At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis, Bioconjug Chem, vol.19, p.958, 2008.

E. H. Appelman, Solvent extraction studies of interhalogen compounds of astatine, J Phys Chem, vol.65, p.325, 1961.

S. Fischer, R. Dreyer, and S. Albrecht, Pseudohalogen compounds of astatine: Synthesis and characterization of At/I/-tricyanomethanide-and At/I/-azide-compounds, J Radioanal Nucl Chem, vol.117, p.275, 1987.

R. Dreyer, I. Dreyer, and S. Fischer, Synthesis and characterization of cationic astatine compounds with sulphurcontaining ligands stable in aqueous solutions, J Radioanal Nucl Chem, vol.96, p.333, 1985.

S. Fischer, R. Dreyer, and H. Hussein, Synthesis and first characterization of cationic At/I/-compounds with selenium-containing neutral ligands, J Radioanal Nucl Chem, vol.119, p.181, 1987.

R. Ludwig, R. Dreyer, and S. Fisher, First investigation of complex formation of At(I) with phosphorous organic compounds, Radiochim Acta, vol.47, p.129, 1989.

S. Milesz, M. Jovchev, and D. Schumann, The EDTA complexes of astatine, J Radioanal Nucl Chem, vol.127, p.193, 1988.

S. Milesz, Y. V. Norseev, and Z. Szü-cs, Characterization of DTPA complexes and conjugated antibodies of astatine, J Radioanal Nucl Chem, vol.137, p.365, 1989.

D. Schumann, S. Milesz, and M. Jovchev, Nitrilotriacetate complex of univalent astatine, Radiochim Acta, vol.56, p.173, 1992.

L. Ning, J. Jiannan, and M. Shangwu, Preparation and preliminary evaluation of astatine-211 labeled IgG via DTPA anhydride, J Radioanal Nucl Chem, vol.227, p.187, 1998.

R. Ludwig, S. Fischer, and R. Dreyer, Complex formation equilibria between astatine(I) and sulphur-containing chelating ligands, Polyhedron, vol.10, p.11, 1991.

A. T. Yordanov, K. Deal, and K. Garmestani, Synthesis and biodistribution study of a new 211-At-calix[4]arene complex, J Label Compd Radiopharm, vol.43, p.1219, 2000.

J. Champion, C. Alliot, and S. Huclier, Determination of stability constants between complexing agents and At(I) and At(III) species present at ultra-trace concentrations, Inorg Chim Acta, vol.362, p.2654, 2009.
URL : https://hal.archives-ouvertes.fr/in2p3-00382733

N. Greenwood and A. Earnshaw, The halogens: Fluorine, Chlorine, Bromine, Iodine and Astatine, vol.789, 1997.

O. R. Pozzi and M. R. Zalutsky, Alpha-particle-induced radiolytic effects on the chemical behavior of (211)At, J Nucl Med, vol.3, p.1190, 2007.

K. Berei and L. Vasáros, Recent Advances in the Organic Chemistry of Astatine. In: PATAI'S Chemistry of Functional Groups, John Wiley and Sons, 2009.

H. H. Coenen and S. M. Moerlein, Stö cklin G. No-carrier added radiohalogenation methods with heavy halogens, Radiochim Acta, vol.34, p.47, 1983.

B. L. Liu, Y. T. Jin, and Z. H. Liu, Halogen exchanges using crown ethers: Synthesis and preliminary biodistribution of 6-[ 211 At]astatomethyl-19-norcholest-5(10)-en-3 beta-ol, Int J Appl Radiat Isot, vol.36, p.561, 1985.

I. Brown, R. N. Carpenter, and E. Link, Potential diagnostic and therapeutic agents for malignant melanoma: Synthesis of heavy radiohalogenated derivatives of methylene blue by electrophilic and nucleophilic methods, J Radioanal Nucl Chem Lett, vol.107, p.337, 1986.

G. J. Meyer, A. Walte, and S. R. Sriyapureddy, Synthesis and analysis of 2-[ 211 At]-l-phenylalanine and 4-[ 211 At]-lphenylalanine and their uptake in human glioma cell cultures in-vitro, Appl Radiat Isot, vol.68, p.1060, 2010.

G. Visser and E. L. Diemer, The reaction of astatine with aromatic diazonium compounds, Radiochem Radioanal Lett, vol.51, p.135, 1982.

G. J. Meyer, K. Rössler, and G. Stöcklin, Reaction of aromatic diazonium salts with carrier-free radioiodine and astatine. Evidence for complex formation, J Am Chem Soc, vol.101, p.3121, 1979.

G. Wunderlich, S. Fischer, and R. Dreyer, A simple method for labelling proteins with 211 At via diazotized aromatic diamine, J Radioanal Nucl Chem Lett, vol.117, p.197, 1987.

Y. V. Norseyev, D. D. Nhan, and V. A. Khalkin, The preparation of astatine labelled tyrosine using an electrophilic reaction, J Radioanal Nucl Chem, vol.94, p.185, 1985.

Y. V. Norseev, Synthesis of astatine-tagged methylene blue, a compound for fighting micrometastases and individual cells of melanoma, J Radioanal Nucl Chem, vol.237, p.155, 1998.

G. Visser, E. L. Diemer, and F. M. Kaspersen, The preparation and stability of astatotyrosine and astato-iodotyrosine, Int J Appl Radiat Isot, vol.30, p.749, 1979.

G. Visser, E. Diemer, and F. M. Kaspersen, The preparation of aromatic astatine compounds through aromatic mercury compounds part II: Astatination of pyrimidines and steroids, J Label Compd Radiopharm, vol.18, p.799, 1981.

G. Vaidyanathan, D. J. Affleck, and K. L. Alston, A kit method for the high level synthesis of [ 211 At]MABG, Bioorg Med Chem, vol.15, p.3430, 2007.

G. Vaidyanathan, D. J. Affleck, and M. R. Zalutsky, Monoclonal antibody F(ab¢) 2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: In vivo comparison of iodinated and astatinated fragments, Nucl Med Biol, vol.21, p.105, 1994.

P. K. Garg, C. S. John, and M. R. Zalutsky, Preparation and preliminary evaluation of 4-[ 211 At]astato-N-piperidinoethyl benzamide, Nucl Med Biol, vol.22, p.467, 1995.

G. Vaidyanathan, R. H. Larsen, and M. R. Zalutsky, 5-[ 211 At]Astato-2'-deoxyuridine, an {alpha}-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation, Cancer Res, vol.56, p.1204, 1996.

A. S. Narula and M. R. Zalutsky, No-carrier added astatination of N-succinimidyl-3-(tri-n-butylstannyl) benzoate (ATE) via electrophilic destannylation, Radiochim Acta, vol.47, p.131, 1989.

J. F. Valliant, K. J. Guenther, and A. S. King, The medicinal chemistry of carboranes, Coord Chem Rev, vol.232, p.173, 2002.

D. S. Wilbur, M. R. Zalutsky, and T. J. Wedge, Reagents for astatination of biomolecules: Comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds, Bioconjug Chem, vol.15, p.203, 2004.

D. S. Wilbur, At]Astatine-labeled compound stability: Issues with released [ 211 At]astatide and development of labeling reagents to increase stability, Current Radiopharm, vol.1, p.144, 2008.

R. H. Larsen, S. Slade, and M. R. Zalutsky, Blocking [ 211 At]astatide accumulation in normal tissues: Preliminary evaluation of seven potential compounds, Nucl Med Biol, vol.25, p.351, 1998.

J. G. Hamilton, C. W. Asling, and W. M. Garrison, Destructive action of astatine 211 (element 85) on the thyroid gland of the rat, Proc Soc Exp Biol Med, vol.73, p.51, 1950.

P. W. Durbin, C. W. Asling, and M. E. Johnston, The induction of tumors in the rat by astatine-211, Radiat Res, vol.9, p.378, 1958.

. Guerard and . Al,

R. E. Mclendon, G. E. Archer, and P. K. Garg, Radiotoxicity of systematically administered [ 211 At]astatide in B6C3F1 and BALB/c (nu/nu) mice: A long-term survival study with histologic analysis, Int J Radiat Oncol Biol Phys, vol.35, p.69, 1996.

M. R. Zalutsky, D. A. Reardon, and O. R. Pozzi, Targeted alpha-particle radiotherapy with 211 At-labeled monoclonal antibodies, Nucl Med Biol, vol.34, p.779, 2007.

C. Aaij, W. Tschroots, and L. Lindner, The preparation of astatine labelled proteins, Int J Appl Radiat Isot, vol.26, p.25, 1975.

A. T. Vaughan and J. H. Fremlin, The preparation of astatine labelled proteins using an electrophilic reaction, Int J Nucl Med Biol, vol.5, p.229, 1978.

A. T. Vaughan and J. H. Fremlin, The preparation of astatotyrosine, Int J Appl Radiat Isot, vol.28, p.595, 1977.

G. Visser, E. L. Diemer, and F. M. Kaspersen, The preparation and stability of 211 At-astato-imidazoles, Int J Appl Radiat Isot, vol.31, p.275, 1980.

G. Visser, E. L. Diemer, and F. M. Kaspersen, The nature of the astatine-protein bond, Int J Appl Radiat Isot, vol.32, p.905, 1981.

A. M. Friedman, M. R. Zalutsky, and F. W. Fitch, Preparation of a biologically stable and immunogenically competent astatinated protein, Int J Nucl Med Biol, vol.4, p.219, 1977.

M. R. Zalutsky and A. S. Narula, Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate, Int J Rad Appl Instrum A, vol.39, p.227, 1988.

O. R. Pozzi and M. R. Zalutsky, Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211 At alpha-particles, J Nucl Med, vol.46, p.700, 2005.

M. R. Zalutsky, D. A. Reardon, and G. Akabani, Clinical experience with alpha-particle emitting 211 At: Treatment of recurrent brain tumor patients with 211 At-labeled chimeric antitenascin monoclonal antibody 81C6, J Nucl Med, vol.49, p.30, 2008.

C. J. Reist, C. F. Foulon, and K. Alston, Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using Nsuccinimidyl 5-[ 211 At]astato-3-pyridinecarboxylate, Nucl Med Biol, vol.26, p.405, 1999.

G. Vaidyanathan, D. J. Affleck, and D. D. Bigner, N-succinimidyl 3-[ 211 At]astato-4-guanidinomethylbenzoate: An acylation agent for labeling internalizing antibodies with alpha-particle emitting 211 At, Nucl Med Biol, vol.30, p.351, 2003.

S. W. Hadley, D. S. Wilbur, and M. A. Gray, Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: Comparisons in vivo with the p-[ 125 I]iodobenzoyl conjugate, Bioconjug Chem, vol.2, p.171, 1991.

P. K. Garg, C. L. Harrison, and M. R. Zalutsky, Comparative tissue distribution in mice of the alpha-emitter 211 At and 131 I as labels of a monoclonal antibody and F(ab¢) 2 fragment, Cancer Res, vol.50, p.3514, 1990.

V. S. Talanov, A. T. Yordanov, and K. Garmestani, Preparation and in vivo evaluation of novel linkers for 211 At labeling of proteins, Nucl Med Biol, vol.31, p.1061, 2004.

V. S. Talanov, K. Garmestani, and C. Regino, Preparation and in vivo evaluation of a novel stabilized linker for 211 At labeling of protein, Nucl Med Biol, vol.33, p.469, 2006.

A. T. Yordanov, K. Garmestani, and M. Zhang, Preparation and in vivo evaluation of linkers for 211 At labeling of humanized anti-Tac, Nucl Med Biol, vol.28, p.845, 2001.

D. S. Wilbur, M. Chyan, and D. K. Hamlin, Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination, Bioconjug Chem, vol.18, p.1226, 2007.

D. S. Wilbur, M. Chyan, and D. K. Hamlin, Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues, Nucl Med Biol, vol.37, p.167, 2010.

D. S. Wilbur, M. Chyan, and D. K. Hamlin, Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in 211 At-and 125 I-labeled closo-decaborate(2-) conjugates of fab¢ as a means of decreasing kidney retention, Bioconjug Chem, vol.22, p.1089, 2011.

G. Vaidyanathan, D. Affleck, and P. Welsh, Radioiodination and astatination of octreotide by conjugation labeling, Nucl Med Biol, vol.27, p.329, 2000.

G. Vaidyanathan, A. Boskovitz, and S. Shankar, Radioiodine and 211 At-labeled guanidinomethyl halobenzoyl octreotate conjugates: Potential peptide radiotherapeutics for somatostatin receptor-positive cancers, Peptides, vol.25, p.2087, 2004.

G. Vaidyanathan, D. J. Affleck, and M. Schottelius, Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211 At via a tin precursor, Bioconjug Chem, vol.17, p.195, 2006.

H. P. Lesch, M. U. Kaikkonen, and J. T. Pikkarainen, Avidinbiotin technology in targeted therapy, Expert Opin Drug Deliv, vol.7, p.551, 2010.

C. F. Foulon, B. W. Schoultz, and M. R. Zalutsky, Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: Biotinyl-3-[ 211 At]astatoanilide, Nucl Med Biol, vol.24, p.135, 1997.

C. F. Foulon, K. L. Alston, and M. R. Zalutsky, Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy, Nucl Med Biol, vol.25, p.81, 1998.

D. S. Wilbur, D. K. Hamlin, and M. Chyan, Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl-and nidocarboranyl-biotin derivatives, Bioconjug Chem, vol.15, p.601, 2004.

D. S. Wilbur, M. Chyan, and D. K. Hamlin, Reagents for astatination of biomolecules. 3. Comparison of closodecaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211, Bioconjug Chem, vol.20, p.591, 2009.

S. Lindegren, H. Andersson, and L. Jacobsson, Synthesis and biodistribution of 211 At-labeled, biotinylated, and charge-modified poly-L-lysine: Evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy, Bioconjug Chem, vol.13, p.502, 2002.

S. Lindegren, B. Karlsson, and L. Jacobsson, At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-lysine as multicarriers, Clin Cancer Res, vol.9, issue.211, p.3873, 2003.

S. Frost, T. Bä-ck, and N. Chouin, In vivo distribution of avidin-conjugated MX35 and 211 At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal a-radioimmunotherapy, Cancer Biother Radiopharm, vol.26, p.727, 2011.

R. H. Larsen, K. M. Murud, and G. Akabani, 211 At-and 131 Ilabeled bisphosphonates with high in vivo stability and bone accumulation, J Nucl Med, vol.40, p.1197, 1999.

G. Vaidyanathan and M. R. Zalutsky, 1-(m-[ 211 At]astatobenzyl)guanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation, Bioconjug Chem, vol.3, p.499, 1992.

R. H. Larsen, S. P. Hassfjell, and P. Hoff, 211-At-labelling of polymer particles for radiotherapy: Synthesis, purification and stability, J Label Compd Radiopharm, vol.33, p.977, 1993.

R. H. Larsen, P. Hoff, and I. B. Vergote, Alpha-particle radiotherapy with 211 At-labeled monodisperse polymer particles, 211 At-labeled IgG proteins, and free 211 At in a murine intraperitoneal tumor model, Gynecol Oncol, vol.57, p.9, 1995.

J. Kucka, M. Hrubý, and C. Konák, Astatination of nanoparticles containing silver as possible carriers of 211 At, Appl Radiat Isot, vol.64, p.201, 2006.

K. B. Hartman, D. K. Hamlin, and D. S. Wilbur, 211 AtCl@US-tube nanocapsules: A new concept in radiotherapeuticagent design, Small, vol.3, p.1496, 2007.

R. H. Larsen, G. Akabani, and P. Welsh, The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro, Radiat Res, vol.149, p.155, 1998.

G. Akabani, S. Carlin, and P. Welsh, , p.211

, At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction, Nucl Med Biol, vol.33, p.333, 2006.

E. Aurlien, Y. Kvinnsland, and R. H. Larsen, Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation

, Int J Radiat Biol, vol.78, p.133, 2002.

T. Petrich, Z. Korkmaz, and D. Krull, , p.211

, At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin, Eur J Nucl Med Mol Imaging, vol.37, p.851, 2010.

M. Nestor, M. Sundström, and M. Anniko, Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas, Nucl Med Biol, vol.38, p.103, 2011.

A. Orlova, A. Sjö-strom, and O. Lebeda, Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells, Anticancer Res, vol.24, p.4035, 2004.

A. K. Claesson and L. Stenerlö-w-b,-jacobsson, Relative biological effectiveness of the alpha-particle emitter (211)At for double-strand break induction in human fibroblasts, Radiat Res, vol.167, p.312, 2007.

K. Claesson, K. Magnander, and H. Kahu, RBE of a-particles from 211 At for complex DNA damage and cell survival in relation to cell cycle position, Int J Rad Biol, vol.87, p.372, 2011.

M. Zhang, Z. Yao, and Z. Zhang, The anti-CD25 monoclonal antibody 7G7/B6, armed with the a-emitter 211 At, provides effective radioimmunotherapy for a murine model of leukemia, Cancer Res, vol.66, p.8227, 2006.

Z. Zhang, M. Zhang, and K. Garmestani, Effective treatment of a murine model of adult T-cell leukemia using 211 At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25, Blood, vol.108, p.1007, 2006.

M. Zhang, Z. Yao, and H. Patel, Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1, Proc Natl Acad Sci U S A, vol.104, p.8444, 2007.

J. Cheng, T. Ekberg, and . Engströ-m-m, Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma, Laryngoscope, vol.117, p.1013, 2007.

M. K. Robinson, C. Shaller, and K. Garmestani, Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the a-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies, Clin Cancer Res, vol.14, p.875, 2008.

J. Elgqvist, H. Andersson, and P. Bernhardt, Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211 At-MX35 F(ab¢) 2, Int J Radiat Oncol Biol Phys, vol.66, p.1228, 2006.

J. Elgqvist, H. Andersson, and T. Back, {alpha}-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose, J Nucl Med, vol.47, p.1342, 2006.

J. Elgqvist, H. Andersson, and T. Bä-ck, Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab¢) 2 : Therapeutic efficacy and myelotoxicity, Nucl Med Biol, vol.33, p.1065, 2006.

J. Elgqvist, H. Andersson, and H. Jensen, Repeated intraperitoneal a-radioimmunotherapy of ovarian cancer in mice, J Oncol, vol.2010, p.1, 2010.

A. Gustafsson, T. Bä-ck, and J. Elgqvist, Comparison of therapeutic efficacy and biodistribution of 213 Bi-and 211 Atlabeled monoclonal antibody MX35 in an ovarian cancer model, Nucl Med Biol, vol.39, p.15, 2012.

M. R. Zalutsky, R. E. Mclendon, and P. K. Garg, Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate, Cancer Res, vol.54, p.4719, 1994.

M. R. Zalutsky, M. G. Stabin, and R. H. Larsen, Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an a-particle-emitting immunoconjugate, Nucl Med Biol, vol.24, p.255, 1997.

S. Palm, T. Back, and I. Claesson, Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice, Int J Radiat Oncol Biol Phys, vol.69, p.572, 2007.

A. Boskovitz, R. E. Mclendon, and T. Okamura, Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of [alpha]-particle-emitting 211 Atlabeled trastuzumab, Nucl Med Biol, vol.36, p.659, 2009.

H. Andersson, E. Cederkrantz, and T. Bä-ck, Intraperitoneal {alpha}-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of 211 At-MX35 F(ab¢) 2 -a phase I study, J Nucl Med, vol.50, p.1153, 2009.

J. G. Hamilton and M. H. Soley, A comparison of the metabolism of iodine and of element 85 (eka-iodine), Proc Natl Acad Sci U S A, vol.26, p.483, 1940.

D. S. Wilbur, M. S. Thakar, and D. K. Hamlin, Reagents for astatination of biomolecules. 4. Comparison of maleimidocloso-decaborate(2-) and meta-[ 211 At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [ 211 At]astatine, Bioconjug Chem, vol.20, 1983.

F. Guerard, H. Rajerison, and A. Faivre-chauvet, Radiolabelling of proteins with stabilised hypervalent astatine-211: Feasability and stability, J Nucl Med, vol.52, p.1486, 2011.

F. Haddad, J. Barbet, and J. F. Chatal, The ARRONAX project, Current Radiopharm, vol.4, p.186, 2011.

. Guerard and . Al,